We are passionate about identifying, developing and bringing to market novel drugs that address unmet medical needs in orphan oncology and have a clear development and market pathway.

At Ascelia Pharma, we believe that partnerships are unique opportunities to combine our strengths and capabilities with those of others to the benefit of patients and healthcare systems worldwide.

Opportunities for innovators and industry partners

We pursue partnerships within orphan oncology drug innovation, development and commercialization.

From universities and biotech companies, to scientists and entrepreneurs, we believe joint efforts are key to making new and better options available for cancer patients – either to supplement our pipeline or to accelerate research, development or commercialization of our current pipeline.

While we continue to prepare the regulatory filing and approval of Orviglance, our orphan liver MRI contrast agent, we seek commercialization partners for global and regional launches, including the US.

For Oncoral, an oral irinotecan chemotherapy, we are exploring partnerships for clinical development and commercialization.

We would be pleased to discuss these and other partnerships or collaboration opportunities.

Contact us at